CMPX | Compass Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.6100 - 1.8616
52 Week Range	0.7650 - 2.3400
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	549,390
Average Volume	435,651
Shares Outstanding	137,589,000
Market Cap	235,277,190
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-04-05

Valuation
Profitability
Growth
Health
P/E Ratio	-4.89
Forward P/E Ratio	N/A
EPS	-0.35
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	32
Country	USA
Website	CMPX

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

CMPX's peers: ASLN, IDYA, ANAB, MGTX, KROS, FIXX, GLUE, NAMS, IVA, CGEM, PEPG, TYRA, VIGL, PRTC, AVTE, ELVN, MLTX, GPCR, REPL, NVCT, LYRA, KRON, GOSS, GNLX, IMRX, IOBT, MIST, OMGA, URGN, PMN

*Chart delayed

Analyzing fundamentals for CMPX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see CMPX Fundamentals page.

Watching at CMPX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CMPX Technicals page.